menu

QuintilesIMS Blog

Fresh ideas and insights from our experts around the globe

distribution
Brazilians flock to pharmacies: How healthcare companies can bolster sales by embracing this shifting shopper trend
Filtered by 'Biosimilars' ×
Ray Huml
With patent expirations looming, biologic companies must innovate – or litigate – to protect their market share.
Read More
Ray Huml
Ray Huml
Ray Huml
A look at the six challenges companies face when pursuing this potentially lucrative development path.
Read More
Nigel Rulewski
March 6, 2015 was a landmark day for the biosimilar manufacturers. It is the day that U.S. Food and Drug Administration (FDA) approved a biosimilar version of filgrastim, making it the first biosimilar product to enter the U.S. market. The approval was no great surprise. An abbreviated licensure pathway for biosimilars approval in the U.S. was established in 2010 as part of the Affordable Care Act, and filgrastim offered an attractive package of attributes making it a prime candidate for FDA’s first step into this new product category. A biosimilar version of filgrastim has been on the European market for years, and the makers can provide hundreds of thousands of days of patient outcomes data, post approval, which provides FDA with deep assurances around its safety and efficacy. I...
Read More
Adrian McKemey
In this post, I will examine outcomes evaluations and how they can help biopharma demonstrate value and outcomes at a local level in the UK. For biopharma, proving the value of a drug is key to its success in the local health economy. During the process of determining a drug’s effectiveness within a local heath economy it is important that all potential data sources are utilised when developing a case for funding with decision makers and a local outcomes assessment can be an important element of this case presentation. With this in mind, outcomes evaluations and outcomes audits are suitable methods for proving a drug’s value and measuring treatment effectiveness using observational data.  We have previously discussed outcomes audits in detail, however this approach looks at data...
Read More